Navigation Links
Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients
Date:12/4/2008

Side effects similar to those seen with standard dose of daunorubicin, study shows

THURSDAY, Dec. 4 (HealthDay News) -- A high dose of the chemotherapy drug daunorubicin prolonged survival for patients with previously untreated acute myeloid leukemia (AML), preliminary results of a study sponsored by the U.S. National Cancer Institute (NCI) show.

AML is a cancer of the blood and bone marrow. This study included 633 patients, aged 16 to 60, who were randomly assigned to receive either high-dose or standard-dose daunorubicin.

Both doses were given in combination with another chemotherapy drug called ara-C (cytarabine). The patients in the high-dose group received 90 milligrams of daunorubicin per square meter of body surface area (90 mg/m2) on each of the first three days of treatment. The standard dose is 45 mg/m2.

Patients in the high-dose group had a median overall survival of 23.7 months, compared to 15.1 months for those in the standard-dose group. Both groups had similar frequencies of serious treatment-related toxicity, according to the study, conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

"The findings of this large clinical trial are important, because they will likely change practice and improve the outcome for many patients with AML," Dr. Martin Tallman, chairman of the ECOG leukemia committee and a professor of medicine at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, said in an NCI news release.

Daunorubicin is already FDA-approved for treatment of AML, which means that patients with the disease may gain immediate benefit from the findings.

More than 13,000 people in the United States will be diagnosed with AML in 2008. Most cases occur in adults, and about half occur in those younger than 60. Only about one-third of AML patients survive the disease, and the odds of survival decrease with age.

More information

The American Cancer Society has more about acute myeloid leukemia.



-- Robert Preidt



SOURCE: U.S. National Cancer Institute, news release, Nov. 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Higher rates of mental illness among the homeless in Western countries
2. Risk of death may be higher with drug commonly used during cardiac surgery
3. Potassium loss from blood pressure drugs may explain higher risk of adult diabetes
4. Avandias Heart Risk Higher Than Others in Its Class
5. TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
6. Physicians Anticipate Higher Prescribing Based on JUPITER Study
7. Non-AIDS Cancer Risk Higher for Those With HIV
8. Death Rates Higher for Minority Children Awaiting Heart Transplant
9. Mesa Labs Reports Higher Quarterly Sales and Earnings
10. Rural women are at higher risk of blood pressure disorders during pregnancy
11. Liver transplant recipients have higher cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... ... 2017 , ... Miro is the ultimate smart media center that offers a ... TV shows and much more apps for user exploration. Its innovative acoustic design with ... 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi connection ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... ... 26, 2017 , ... Today, A' Design Awards & Competition ... Social Design Awards. , The 7th A' Social Design Award is open ... worldwide with realized projects and conceptual works. , The first phase of the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  International Biophysics Corporation, a global medical device ... announced a 34% revenue growth in 2016 when compared to ... sales.  This growth was fueled by its AffloVest® sales in ... the expansion of its global sales of surgical product lines. ... "As we enter our 25 th year in delivering ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
(Date:2/27/2017)... February 27, 2017 Leading Countries, Technologies and ... is expected to grow at a CAGR of 8.9% from 2016-2021 ... grow at a CAGR of 9.1% from 2016 to 2027. The ... ... will benefit you Read on to discover how you can ...
Breaking Medicine Technology: